Philadelphia, September 8 – The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients ...
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announces the following cancer researchers as the recipients of the organization’s annual scientific leadership and mentorship awards. Through its ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results